2019冠状病毒病:基本原理、年表和疫苗演变

Q3 Medicine
Y. Thirupathaiah, A. Chandel
{"title":"2019冠状病毒病:基本原理、年表和疫苗演变","authors":"Y. Thirupathaiah, A. Chandel","doi":"10.1097/MRM.0000000000000289","DOIUrl":null,"url":null,"abstract":"The coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus, which is recognized as Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The recent pandemic caused by SARS-CoV-2 is a concern of major public health emergency globally. The virus is highly contagious, enters through nasopharyngeal route into lungs and infects respiratory tracts and later disseminate to other organs in the body. If body immune response fails to eliminate or over responds to infection in affected persons, the condition turns to severe acute respiratory syndrome or pneumonia, multiple organ failure, septic shock and finally end-up with life in critical cases. Currently, there are no antiviral drugs available to eradicate the complete infection and the only treatment available to patients with critical illness is providing oxygen supply through ventilators along with few antiviral and anti-inflammatory drugs to relieve from the symptoms. Recently developed COVID-19 vaccines are available to the public in several countries for protecting against SARS-CoV-2. Further, researchers are vigorously being focused on development of novel vaccines, recombinant interferons, monoclonal antibodies against virus, finding of antiviral drugs to block coronaviral specific structural proteins or multiplication in infected persons, drugs for suppression of over production of pro-inflammatory cytokines by the human body and disease mechanisms of virus. However, because of combined treatment strategies and reduced pathogenicity of SARS-CoV-2, the current mortality rate has been reduced to less than 1--1.5% globally from 5 to 6% of initial COVID-19 pandemic. Unfortunately, sudden increase in number of cases in several countries and evolution of new pathogenic strains of SARS-CoV-2 variants from existing strains make another challenging task both for public and scientific communities. Hence, public health officials are recommending public to continue social distancing, avoid contact with infected persons, isolation and quarantine of exposed persons till COVID-19 prevention is under control.","PeriodicalId":49625,"journal":{"name":"Reviews in Medical Microbiology","volume":"9 1","pages":"246 - 254"},"PeriodicalIF":0.0000,"publicationDate":"2021-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Coronavirus disease 2019: fundamentals, chronology and vaccine evolution\",\"authors\":\"Y. Thirupathaiah, A. Chandel\",\"doi\":\"10.1097/MRM.0000000000000289\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus, which is recognized as Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The recent pandemic caused by SARS-CoV-2 is a concern of major public health emergency globally. The virus is highly contagious, enters through nasopharyngeal route into lungs and infects respiratory tracts and later disseminate to other organs in the body. If body immune response fails to eliminate or over responds to infection in affected persons, the condition turns to severe acute respiratory syndrome or pneumonia, multiple organ failure, septic shock and finally end-up with life in critical cases. Currently, there are no antiviral drugs available to eradicate the complete infection and the only treatment available to patients with critical illness is providing oxygen supply through ventilators along with few antiviral and anti-inflammatory drugs to relieve from the symptoms. Recently developed COVID-19 vaccines are available to the public in several countries for protecting against SARS-CoV-2. Further, researchers are vigorously being focused on development of novel vaccines, recombinant interferons, monoclonal antibodies against virus, finding of antiviral drugs to block coronaviral specific structural proteins or multiplication in infected persons, drugs for suppression of over production of pro-inflammatory cytokines by the human body and disease mechanisms of virus. However, because of combined treatment strategies and reduced pathogenicity of SARS-CoV-2, the current mortality rate has been reduced to less than 1--1.5% globally from 5 to 6% of initial COVID-19 pandemic. Unfortunately, sudden increase in number of cases in several countries and evolution of new pathogenic strains of SARS-CoV-2 variants from existing strains make another challenging task both for public and scientific communities. Hence, public health officials are recommending public to continue social distancing, avoid contact with infected persons, isolation and quarantine of exposed persons till COVID-19 prevention is under control.\",\"PeriodicalId\":49625,\"journal\":{\"name\":\"Reviews in Medical Microbiology\",\"volume\":\"9 1\",\"pages\":\"246 - 254\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reviews in Medical Microbiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/MRM.0000000000000289\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews in Medical Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/MRM.0000000000000289","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

2019冠状病毒病(COVID-19)是由一种新型冠状病毒引起的,这种冠状病毒被认为是严重急性呼吸综合征冠状病毒-2 (SARS-CoV-2)。最近由SARS-CoV-2引起的大流行是全球关注的重大突发公共卫生事件。该病毒具有高度传染性,通过鼻咽途径进入肺部,感染呼吸道,然后传播到身体其他器官。如果机体免疫反应不能消除或对感染者的感染反应过度,病情就会转变为严重急性呼吸综合征或肺炎、多器官衰竭、感染性休克,危重病例最终死亡。目前,没有抗病毒药物可以完全根除感染,对危重患者的唯一治疗方法是通过呼吸机提供氧气,同时使用少量抗病毒和抗炎药物来缓解症状。最近开发的COVID-19疫苗已在一些国家向公众提供,用于预防SARS-CoV-2。此外,研究人员正积极致力于开发新型疫苗、重组干扰素、抗病毒单克隆抗体、寻找阻断冠状病毒特异性结构蛋白或在感染者体内增殖的抗病毒药物、抑制人体过度产生促炎细胞因子的药物和病毒的发病机制。然而,由于采取了综合治疗策略和降低了SARS-CoV-2的致病性,目前全球死亡率已从最初的COVID-19大流行的5%至6%降至1.5%以下。不幸的是,一些国家的病例数量突然增加,以及从现有菌株演变成新的SARS-CoV-2变异致病性菌株,使公众和科学界面临另一项具有挑战性的任务。因此,公共卫生官员建议公众继续保持社交距离,避免与感染者接触,隔离和检疫暴露者,直到COVID-19的预防得到控制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Coronavirus disease 2019: fundamentals, chronology and vaccine evolution
The coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus, which is recognized as Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The recent pandemic caused by SARS-CoV-2 is a concern of major public health emergency globally. The virus is highly contagious, enters through nasopharyngeal route into lungs and infects respiratory tracts and later disseminate to other organs in the body. If body immune response fails to eliminate or over responds to infection in affected persons, the condition turns to severe acute respiratory syndrome or pneumonia, multiple organ failure, septic shock and finally end-up with life in critical cases. Currently, there are no antiviral drugs available to eradicate the complete infection and the only treatment available to patients with critical illness is providing oxygen supply through ventilators along with few antiviral and anti-inflammatory drugs to relieve from the symptoms. Recently developed COVID-19 vaccines are available to the public in several countries for protecting against SARS-CoV-2. Further, researchers are vigorously being focused on development of novel vaccines, recombinant interferons, monoclonal antibodies against virus, finding of antiviral drugs to block coronaviral specific structural proteins or multiplication in infected persons, drugs for suppression of over production of pro-inflammatory cytokines by the human body and disease mechanisms of virus. However, because of combined treatment strategies and reduced pathogenicity of SARS-CoV-2, the current mortality rate has been reduced to less than 1--1.5% globally from 5 to 6% of initial COVID-19 pandemic. Unfortunately, sudden increase in number of cases in several countries and evolution of new pathogenic strains of SARS-CoV-2 variants from existing strains make another challenging task both for public and scientific communities. Hence, public health officials are recommending public to continue social distancing, avoid contact with infected persons, isolation and quarantine of exposed persons till COVID-19 prevention is under control.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Reviews in Medical Microbiology
Reviews in Medical Microbiology 生物-微生物学
CiteScore
1.80
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊介绍: Reviews in Medical Microbiology is a quarterly review journal which provides a balanced coverage of the whole field of medical microbiology. The Journal publishes state-of-the art reviews, mini-reviews, case presentations and original research from on-going research of the latest developments and techniques in medical microbiology, virology, mycology, parasitology, clinical microbiology, and hospital infection.​ In addition, PhD-Review - a platform for young researchers, and biographical Bio-Sketch articles are also considered. Reviews are concise, authoritative, and readable synthesis of the latest information on its subject, and references are limited to the fifty key sources for full reviews and twenty for mini-reviews. Reviews in Medical Microbiology is the perfect way for both qualified and trainee microbiologists, and researchers and clinicians with an interest in microbiology, to stay fully informed of the latest developments in medical microbiology. The journal is a valuable resource for educational and teaching purposes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信